SARS-CoV-2–specific antibody detection for seroepidemiology: a multiplex analysis approach accounting for accurate seroprevalence

G den Hartog, RM Schepp, M Kuijer… - The Journal of …, 2020 - academic.oup.com
Background The COVID-19 pandemic necessitates better understanding of the kinetics of
antibody production induced by infection with SARS-CoV-2. We aimed to develop a high-…

[HTML][HTML] Alternative strategies to increase the immunogenicity of COVID-19 vaccines in kidney transplant recipients not responding to two or three doses of an mRNA …

…, LLA van Dijk, N Rots, G Smits, M Kuijer… - The Lancet Infectious …, 2023 - thelancet.com
Background An urgent need exists to improve the suboptimal COVID-19 vaccine response
in kidney transplant recipients (KTRs). We aimed to compare three alternative strategies with …

[HTML][HTML] Seropositivity to Nucleoprotein to detect mild and asymptomatic SARS-CoV-2 infections: A complementary tool to detect breakthrough infections after COVID …

…, M van Boven, HE de Melker, J van Vliet, M Kuijer… - Vaccine, 2022 - Elsevier
Background With COVID-19 vaccine roll-out ongoing in many countries globally, monitoring
of breakthrough infections is of great importance. Antibodies persist in the blood after a …

[HTML][HTML] SARS-CoV-2 Spike S1-specific IgG kinetic profiles following mRNA or vector-based vaccination in the general Dutch population show distinct kinetics

…, D Wong, AJ Wijmenga-Monsuur, G Smits, M Kuijer… - Scientific Reports, 2022 - nature.com
mRNA- and vector-based vaccines are used at a large scale to prevent COVID-19. We
compared Spike S1-specific (S1) IgG antibodies after vaccination with mRNA-based (Comirnaty, …

[HTML][HTML] Reduced antibody acquisition with increasing age following vaccination with BNT162b2: Results from two longitudinal cohort studies in the Netherlands

…, MB Maurik, I Zutt, J van Vliet, R van Bergen, M Kuijer… - Vaccines, 2022 - mdpi.com
Vaccine-induced protection against severe COVID-19, hospitalization, and death is of the
utmost importance, especially in the elderly. However, limited data are available on humoral …

Tolerability, safety and immunogenicity of intradermal delivery of a fractional dose mRNA-1273 SARS-CoV-2 vaccine in healthy adults as a dose sparing strategy

…, JJ Janse, AC Kruithof, MCW Feltkamp, M Kuijer… - medRxiv, 2021 - medrxiv.org
Background There is an urgent need for fair and equitable access to safe and effective
vaccines to end the COVID-19 pandemic. Shortages in reagents and vaccines are a major …

Safety and immunogenicity of intradermal fractional dose administration of the mRNA-1273 vaccine: a proof-of-concept study

…, AC Kruithof, MCW Feltkamp, M Kuijer… - Annals of internal …, 2022 - acpjournals.org
Background: There is an urgent need for fair and equitable access to safe and effective
COVID-19 vaccines. Intradermal (ID) delivery is a dose-sparing technique that can be used to …

[HTML][HTML] Immunogenicity and reactogenicity of intradermal mRNA-1273 SARS-CoV-2 vaccination: a non-inferiority, randomized-controlled trial

…, AC de Kroon, S Azimi, MCW Feltkamp, M Kuijer… - npj Vaccines, 2024 - nature.com
Fractional dosing can be a cost-effective vaccination strategy to accelerate individual and
herd immunity in a pandemic. We assessed the immunogenicity and safety of primary …

Infant antibody levels following 10-valent pneumococcal-protein D conjugate and DTaP-Hib vaccinations in the first year of life after maternal Tdap vaccination: an …

D Barug, GAM Berbers, MA van Houten, M Kuijer… - Vaccine, 2020 - Elsevier
Background Maternal antibody levels after Tdap vaccination during pregnancy may affect
infant primary antibody responses to pertussis, Tetanus toxoid (TT), Diphtheria toxoid (DT) …

[HTML][HTML] Protective mucosal SARS-CoV-2 antibodies in the majority of the general population in the Netherlands

…, RM Schepp, GP Smits, DW Beljaars, M Kuijer… - Mucosal …, 2024 - Elsevier
Highlights • The majority of the Dutch population (1–90 years of age) has parenteral and
Omicron SARS-CoV-2–specific mucosal immunoglobulin (Ig) G antibodies. • The presence of …